Cordex Pharma, Inc. announced today that it has filed a formulation patent covering its lead product, ATPace.
ATPace is a stable liquid formulation of adenosine triposphate (ATP) for intravenous administration. ATPace is being developed as a therapeutic drug for the acute management of paroxysmal supraventricular tachycardia (PSVT) as well as a diagnostic test for the identification of patients with bradycardic (slow heart rate) syncope who may benefit from pacemaker therapy.
The details can be read here.
No comments:
Post a Comment